Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>Left ventricular (LV) thrombus is increasingly detected in patients with and without ischaemic heart disease due to the increased availability of cardiac magnetic resonance imaging. Risk factors include anterior ST elevation myocardial infarction, delayed reperfusion therapy, and non‐ischaemic cardiomyopathy with severe LV systolic dysfunction. We aimed to report the characteristics and outcomes of patients with LV thrombus treated with either vitamin K antagonist (VKA) or direct oral anticoagulants (DOAC) with a view to describing differences in efficacy, specifically, subsequent thromboembolic events, thrombus resolution, and also side effects of therapy including clinically significant bleeding.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and results</h3><p>We conducted a retrospective, observational cohort study of patients diagnosed with LV thrombus between 1 December 2012 and 30 June 2018 and treated with either DOAC or VKA. We recorded patient demographics, past medical history, prescribed medications, and baseline investigations. The primary outcomes were rates of thromboembolism and clinically significant bleeding, with secondary outcomes of thrombus resolution on repeat cardiac imaging, repeat hospitalization, and all‐cause mortality. During the study period, 84 patients were diagnosed with and managed for LV thrombus. Of these, 62 received VKA and 22 DOAC including 13 prescribed rivaroxaban, eight apixaban, and one dabigatran. Most patients 75 (89%) were male with an average age of 62 ± 14 years. Ischaemic heart disease was the cause of LV impairment in 73 (87%) patients. Baseline characteristics were similar between groups at baseline. Most <i>n</i> = 55 (65%) were co‐prescribed a single antiplatelet agent and 32 (38%) received dual‐antiplatelet therapy. During an average follow‐up of 3.0 ± 1.4 years, there were no statistically significant differences between VKA and DOAC in rates of stroke (2% vs. 0%, <i>P</i> = 0.55), other thromboemboli (2% vs. 0%, <i>P</i> = 0.55), or clinically significant bleeding (10% vs. 0%, <i>P</i> = 0.13). The average interval to cardiac imaging follow‐up was 233 ± 251 days and was not different between groups (<i>P</i> = 0.83), and there was no difference in the rate of resolution of thrombus (76% vs. 65% <i>P</i> = 0.33). Rehospitalization (50% vs. 45%: <i>P</i> = 0.53) and all‐cause mortality (10% vs. 14%; <i>P</i> = 0.61) were also similar. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our data suggest that DOACs are likely to be at least as effective and safe as VKA for stroke prevention in patients with LV thrombus and, despite their lack of a licence for this indication, are therefore likely to represent a reasonable and more convenient option for this setting. The optimal timing and type of anticoagulation for LV thrombus, as well as the role of screening for high‐risk patients, should be tested in prospective, randomized trials.</p></section>

A retrospective assessment of venous recanalization outcomes for oral anticoagulant treatment in deep vein thrombosis

Late recanalisation beyond 24 hours is associated with worse outcome: an observational study

Recanalization after cerebral venous thrombosis. A randomized controlled trial of the safety and efficacy of dabigatran etexilate versus dose-adjusted warfarin in patients with cerebral venous and dural sinus thrombosis

The clinical outcomes of different doses of rivaroxaban in patients with isolated distal deep vein thrombosis

Complication comparison in intermediate-to-high risk venous thromboembolism patients, treated with high vs standard dose apixaban and rivaroxaban after low molecular weight heparin

The Effectiveness and Safety of Rivaroxaban and Edoxaban in the Treatment of Lower Extremity Deep Vein Thrombosis

Direct oral anticoagulants decrease treatment failure for acute lower extremity deep venous thrombosis

Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data

Diagnosis and Treatment of Lower Extremity Venous Thromboembolism: A Review

[Endovascular treatment of deep vein thrombosis of the upper extremities]

Long-Term Efficacy and Safety of Direct Oral Anticoagulants at Reduced Doses in the Secondary Prevention of Venous Thromboembolism and Post-Thrombotic Syndrome

Meta-analysis of Efficacy and Safety of Rivaroxaban for Treatment of Deep Venous Thrombosis

Comparison of the efficacy of rivaroxaban and dabigatran etexilate in preventing venous thrombosis after arthroplasty: A protocol of randomized controlled trial

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

Prophylactic Dose of Rivaroxaban Versus Warfarin for the Treatment of Isolated Calf Muscle Vein Thrombosis: A Retrospective Propensity Score-Matched Analysis

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban—A Case Report

Comparison of Rivaroxaban Mono-Therapy and Standard-Therapy Adjusted by CYP2C9 and VKORC1 Genotypes in Symptomatic Pulmonary Embolism.

Anticoagulants for the treatment of isolated lower limb superficial vein thrombosis a Bayesian network meta-analysis of randomized controlled trials

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus

Pharmacological Thromboprophylaxis for VTE Post-Endovenous Ablation of Varicose Veins: Network Meta-Analysis

Outcome Comparisons of Anticoagulation, Systematic Thrombolysis and Catheter-Directed Thrombolysis in the Treatment of Lower Extremity Acute Deep Venous Thrombosis